close

Enter

Log in using OpenID

Antihypertensive Therapeutics in Major Developed Market Analysis and Treatment, 2021: Hexa Reports

embed
Antihypertensives are a class of drugs which can prevent hypertension and other cardiovascular-related disorders like strokes and myocardial infarction.
Hexa Reports
Market Research Reports and Insightful Company Profiles
Antihypertensive Therapeutics in Major Developed Market
Size, Share, Growth, Treatment, Analysis, Symptoms,
Emerging Trends and Opportunities to 2021
Hypertension is a heart-related disease which results in elevated blood pressure in the arteries. It is also
known as arterial hypertension or high blood pressure. This disease occurs on account of alcohol,
smoking, obesity, and other genetic factors. Although, the disease can be treated with a healthy diet and
exercise, antihypertensives are recommended to control it.
Antihypertensives are a class of drugs which can prevent hypertension and other cardiovascular-related
disorders like strokes and myocardial infarction. They are likely to reduce the heart conditions by 21%.
Beta blockers, thiazide diuretics, ACE inhibitors, calcium channel blockers, and angiotensin II receptor
antagonists (ARBs) are the different types of antihypertensive therapeutics in major developed markets.
Browse Detail Report With TOC @ http://www.hexareports.com/report/antihypertensivetherapeutics-in-major-developed-markets/details
Thiazide diuretics aid in reducing salt and water from the kidneys. They are the first drugs to be
administered for a patient undergoing hypertension treatment. ACE inhibitors reduce serum creatinine
levels better than beta blockers. They are considered the first line of defense against heart-related
disorders. ARBs reduces the risko f myocardial infarction when combined with amlodipine. Beta blockers
Hexa Reports
Market Research Reports and Insightful Company Profiles
are considered risky and can lead to strokes or type-2 diabetes. However, they prevent heart attacks in
persons who have already experienced a heart attack.
The hypertension market was estimated to have earned USD 40 billion of revenue in 2013. The market
will attain USD 37 billion by 2020, owing to the patent expiry of major drugs. It is predicted to grow at a
2.6% CAGR during the period of 2014 to 2017. The market will experience growth on account of fixeddose combination (FDCs) drugs, the rising geriatric population, and a low diagnosis rate.
FDCs include Amturnide, Azor, Twynsta, Exforge Tribenzor, Valturna, Benicar HCT, Tekturna HCT,
Tekamlo, and Edarbyclor. New drugs in the pipeline are AHU377 + valsartan and azilsartan + amlodipine.
Patients undergoing the treatment were known to have reduced levels of blood pressure. Drugs about
to lose their patent are Exforge in 2014, Cozaar in 2010, Tekturna and Tekturna HCT in 2018, Benicar in
2016, and Atacand and Avapro in 2012.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/104209
The hypertension market has evolved from creating drugs to providing step-by-step special treatment
dependent on the seriousness of the disease. The new classes of antihypertensive drugs are able to
protect the kidneys, liver, heart, and brain from internal damage.
Table Of Content
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pathophysiology
2.2 Etiology
2.3 Signs and Symptoms
2.4 Co-Morbidities and Complications
2.5 Diagnosis
2.6 Classification
2.7 Epidemiology
2.8 Prognosis
2.9 Treatment and Management
3 Marketed Products
3.1 Approved Products
3.2 Comparative Efficacy and Safety
4 Product Pipeline
4.1 Overall Pipeline
Hexa Reports
Market Research Reports and Insightful Company Profiles
4.2 Pipeline Analysis by Molecules Type
4.3 Pipeline Analysis by Mechanism of Action Type
4.4 Clinical Trial Failure Rate
4.5 Patient Enrollment and Clinical Trial Size
4.6 Clinical Trial Duration
4.7 Promising Drug Candidates in Pipeline
Browse All Pharmaceuticals & Healthcare Market Research Related Reports @
http://www.hexareports.com/category/pharmaceuticals-and-healthcare-market
5 Market Forecast
5.1 Introduction
5.2 Global Market
5.3 North America
5.4 Top Five European Countries
5.5 Japan
5.6 Drivers and Barriers
6 Deals and Strategic Consolidations
6.1 Licensing Deals
6.2 Co-development Deals
7 Appendix
7.1 Market Forecasts to 2020
7.2 All Pipeline Drugs by Phase
7.3 Abbreviations
7.4 References
7.5 Methodology
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer
Browse Full Report @ http://www.hexareports.com/report/antihypertensive-therapeutics-in-majordeveloped-markets/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Hexa Reports
Market Research Reports and Insightful Company Profiles
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: [email protected]
Our Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/
1/--pages
Report inappropriate content